Zurcher Kantonalbank (Zurich Cantonalbank) - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 94 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Zurcher Kantonalbank (Zurich Cantonalbank) ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$61,299
-21.7%
7,103
-6.0%
0.00%
Q2 2023$78,246
-9.3%
7,560
-4.9%
0.00%
Q1 2023$86,279
-2.3%
7,952
+1.1%
0.00%
Q4 2022$88,279
+5.1%
7,868
-5.0%
0.00%
Q3 2022$84,000
+12.0%
8,2800.0%0.00%
Q2 2022$75,000
-8.5%
8,280
-3.1%
0.00%
Q1 2022$82,000
+30.2%
8,548
+49.5%
0.00%
Q4 2021$63,000
+50.0%
5,7180.0%0.00%
Q3 2021$42,000
-49.4%
5,7180.0%0.00%
Q2 2021$83,000
-29.1%
5,7180.0%0.00%
-100.0%
Q1 2021$117,000
+14.7%
5,7180.0%0.00%0.0%
Q4 2020$102,000
+20.0%
5,7180.0%0.00%0.0%
Q3 2020$85,000
+16.4%
5,718
+63.6%
0.00%0.0%
Q2 2020$73,000
-9.9%
3,4950.0%0.00%0.0%
Q1 2020$81,000
+17.4%
3,495
+30.5%
0.00%0.0%
Q4 2019$69,000
+32.7%
2,6790.0%0.00%
Q3 2019$52,000
+18.2%
2,6790.0%0.00%
Q2 2019$44,000
-27.9%
2,6790.0%0.00%
-100.0%
Q1 2019$61,000
-11.6%
2,6790.0%0.00%0.0%
Q4 2018$69,000
-21.6%
2,6790.0%0.00%0.0%
Q3 2018$88,000
+44.3%
2,6790.0%0.00%0.0%
Q2 2018$61,000
-6.2%
2,6790.0%0.00%0.0%
Q1 2018$65,000
-13.3%
2,6790.0%0.00%0.0%
Q4 2017$75,000
+31.6%
2,679
+61.6%
0.00%0.0%
Q3 2017$57,000
-13.6%
1,6580.0%0.00%0.0%
Q2 2017$66,000
+8.2%
1,6580.0%0.00%0.0%
Q1 2017$61,000
+15.1%
1,6580.0%0.00%0.0%
Q4 2016$53,000
-43.6%
1,658
-36.4%
0.00%0.0%
Q3 2016$94,000
+74.1%
2,607
+9.9%
0.00%0.0%
Q2 2016$54,000
-85.2%
2,372
-79.2%
0.00%
-90.9%
Q2 2014$364,00011,4280.01%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2018
NameSharesValueWeighting ↓
Chescapmanager LLC 1,134,718$23,160,0002.47%
Baupost Group 8,735,168$178,285,0001.42%
Orbimed Advisors 6,219,110$126,932,0001.19%
CM Management, LLC 50,000$1,021,0000.76%
Tekla Capital Management LLC 456,296$9,313,0000.32%
Rock Springs Capital Management LP 682,600$13,932,0000.30%
Virtus ETF Advisers LLC 32,871$671,0000.28%
Cormorant Asset Management, LP 550,000$11,226,0000.25%
DAFNA Capital Management LLC 41,165$840,0000.20%
PEREGRINE CAPITAL MANAGEMENT LLC 484,206$9,883,0000.18%
View complete list of THERAVANCE BIOPHARMA INC shareholders